MRNA vaccines take on glioblastoma: a new hope against brain cancer recurrence?
NCT ID NCT07520214
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests two mRNA vaccines, GV-907 and GV-108, in 9 adults with a specific type of glioblastoma. The goal is to see if the vaccines are safe and can trigger an immune response to prevent the cancer from coming back after standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA vaccines GV-907 and GV-108
What this could lead to
If successful, this could point toward a new way to delay or prevent glioblastoma recurrence using personalized mRNA vaccines.
What could go wrong
This is a very early, small trial with only 9 participants, so results may not apply broadly. The vaccines may not trigger a strong enough immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100050, China